Differences in gene expression between wild type and Hoxa1 knockout embryonic stem cells after retinoic acid treatment or leukemia inhibitory factor (LIF) removal.

TitleDifferences in gene expression between wild type and Hoxa1 knockout embryonic stem cells after retinoic acid treatment or leukemia inhibitory factor (LIF) removal.
Publication TypeJournal Article
Year of Publication2005
AuthorsMartinez-Ceballos E, Chambon P, Gudas LJ
JournalJ Biol Chem
Volume280
Issue16
Pagination16484-98
Date Published2005 Apr 22
ISSN0021-9258
KeywordsAnimals, Biomarkers, Bone Morphogenetic Protein 4, Bone Morphogenetic Proteins, Brain, CCN Intercellular Signaling Proteins, DNA-Binding Proteins, Homeodomain Proteins, Interleukin-6, Leukemia Inhibitory Factor, Mice, Mice, Inbred C57BL, Myeloid Ecotropic Viral Integration Site 1 Protein, Neoplasm Proteins, Octamer Transcription Factor-3, Oligonucleotide Array Sequence Analysis, Oncogene Proteins, Pre-B-Cell Leukemia Transcription Factor 1, Proteins, Proto-Oncogene Proteins, Stem Cells, Transcription Factors, Tretinoin
Abstract

Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3' member of the Hoxa cluster and a retinoic acid (RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells (named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development (e.g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain (e.g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes (e.g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers (e.g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.

DOI10.1074/jbc.M414397200
Alternate JournalJ. Biol. Chem.
PubMed ID15722554
Grant List2U19HDO35466 / HD / NICHD NIH HHS / United States
R01CA43796 / CA / NCI NIH HHS / United States